Our Team

Steve

Jadhav

Steve Jadhav is a highly accomplished International Marketer with extensive experience in healthcare marketing, commercial strategy, and scientific sales engagement, gained over a 20+ year career in the pharmaceutical industry. Known for his strategic vision and results-driven approach, Steve has led major product launches and lifecycle marketing strategies across rare and specialty disease areas, including mucopolysaccharidoses (MPS), ceroid lipofuscinosis (NCL), Phenylketonuria (PKU), endocrine disorders, urological disorders, organ replacement, systemic fungal infections, and lipid disorders.

Most recently at BioMarin, Steve led the enzymes and PKU marketing portfolio across Europe and key international markets, including Turkey, Russia, the Middle East, Canada, and Australia/New Zealand. He was responsible for developing brand strategy, executing campaigns, engaging customers, and optimising commercial performance. His leadership in cross-functional collaboration, stakeholder alignment, and digital channel integration contributed significantly to market growth and commercial success.

Before joining BioMarin, Steve held senior marketing positions at Shire and Astellas Pharma Europe, where he developed impactful pre-launch and launch strategies, created award-winning promotional content, and fostered thought leader engagement and patient advocacy. He also has a strong grounding in medical affairs and medical information from earlier roles with Bayer, Sanofi-Aventis, and Parke-Davis.

Steve’s academic credentials include an MBA from Manchester Business School and a BSc (Hons) in Biochemistry from the University of Surrey. He also holds a recent certification in digital customer acquisition and pharmaceutical marketing strategy. Steve is also a UK Code of Practice syndicate leader for the ABPI (PMCPA).

With deep expertise in data-driven marketing, team leadership, and patient-centric innovation, Steve is passionate about advancing healthcare solutions and driving meaningful outcomes for patients, providers, and the business. He is known for his integrity, collaborative mindset, and ability to navigate complex matrixed environments to deliver measurable impact.

Zlatko

Sisic

Zlatko Sisic is an internationally recognised medical and business leader with over 20 years of experience in the pharmaceutical and biotechnology industries. With a distinct focus on rare diseases, orphan drugs, and advanced therapeutics, he has built an exceptional career spanning clinical leadership, strategic advisory, and executive governance across Europe and global markets.

Zlatko is the Co-Founder and Chief Medical Officer of Oranda Therapeutics and also serves as Managing Director of Orphan Pharma Consulting, a firm he founded to advise rare disease-focused pharma and biotech companies on medical affairs strategy and go-to-market execution. His recent medical leadership at BioCryst Pharmaceuticals was pivotal in launching a novel medicine for hereditary angioedema in Europe, where he built and led a high-performing medical team and drove strategic initiatives that led to regulatory and commercial successes.

Previously, he held senior global roles at BioMarin, where he shaped strategies for therapies targeting metabolic and neurodegenerative disorders such as CLN2 and MPS diseases. His medical leadership contributed to expanded patient access, successful negotiations with reimbursement agencies, and the establishment of major medical education platforms.

Zlatko has also held key medical leadership roles at ViroPharma, Eisai, Actelion, Novartis, Sanofi-Aventis, and Allergan, consistently advancing the therapeutic landscape in areas including pulmonary hypertension and epilepsy.

He is deeply committed to advocacy and governance, serving as Chair of the Board at the Batten Disease Family Association and Trustee of MDS UK Support Group. His board-level and advisory roles demonstrate a profound engagement in both strategic oversight and scientific advancement.

Zlatko obtained a medical degree from the University of Belgrade, an Executive MBA from Oxford Brookes University and a diploma in Translational medicine from King’s College University in London. He is a member of the UK’s Faculty of Pharmaceutical Medicine.

A widely published author, he has contributed to numerous peer-reviewed studies in rare diseases and continues to influence global discourse on patient care and medical innovation.